Literature DB >> 9333017

Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions.

M Kornmann1, T Ishiwata, H G Beger, M Korc.   

Abstract

Fibroblast growth factor (FGF)-1 and -2 are overexpressed in human pancreatic cancer. In this study the role of FGF-5 in human pancreatic cancer was investigated, as FGF-5 has a classical signal sequence for secretion not found in FGF-1 or -2. Northern blot analysis with a 306 bp FGF-5 cDNA revealed the presence of 4.0 kb and 1.6 kb FGF-5 mRNA transcripts in both normal and cancerous pancreatic tissues. Densitometric analysis indicated that 4.0 kb and 1.6 kb FGF-5 mRNA transcripts levels were increased 2.4- and 2.7-fold in the cancers by comparison with normal tissues, respectively (P < 0.002, P < 0.0001). Immunohistochemistry and in situ hybridization demonstrated that FGF-5 localized in the cancer cells, stromal fibroblast and inflitrating macrophages. FGF-5 mRNA was also detected in COLO-357 human pancreatic cancer cells. Furthermore, secreted FGF-5 protein was present in conditioned medium of COLO-357 cells. Exogeneous FGF-5 (0.37 nM) increased the growth of COLO-357 cells by 48% (P < 0.0001) and increased mitogen-activated protein kinase activity. COLO-357 cells expressed the IIIc isoform of the type I FGF receptor, the preferred FGF receptor for FGF-5. These observations suggest that FGF-5 may participate in autocrine and paracrine pathways promoting pancreatic cancer cell growth in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9333017     DOI: 10.1038/sj.onc.1201307

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  34 in total

Review 1.  The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma.

Authors:  Elena Tassi; Anton Wellstein
Journal:  Semin Oncol       Date:  2006-12       Impact factor: 4.929

Review 2.  The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells.

Authors:  M R Moniri; L-J Dai; G L Warnock
Journal:  Cancer Gene Ther       Date:  2014-01-03       Impact factor: 5.987

3.  Fas and Fas-ligand expression in human pancreatic cancer.

Authors:  M Kornmann; T Ishiwata; J Kleeff; H G Beger; M Korc
Journal:  Ann Surg       Date:  2000-03       Impact factor: 12.969

4.  Invasive potential of hepatocellular carcinoma is enhanced by loss of selenium-binding protein 1 and subsequent upregulation of CXCR4.

Authors:  Ping-Ting Gao; Guang-Yu Ding; Xuan Yang; Rui-Zhao Dong; Bo Hu; Xiao-Dong Zhu; Jia-Bin Cai; Yuan Ji; Guo-Ming Shi; Ying-Hao Shen; Jian Zhou; Jia Fan; Hui-Chuan Sun; Cheng Huang
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

5.  Tumor angiogenesis: initiation and targeting - therapeutic targeting of an FGF-binding protein, an angiogenic switch molecule, and indicator of early stages of gastrointestinal adenocarcinomas -.

Authors:  Elena Tassi; Anton Wellstein
Journal:  Cancer Res Treat       Date:  2006-12-31       Impact factor: 4.679

6.  Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker?

Authors:  Andrea Formentini; Sylvia Sander; Stephanie Denzer; Joern Straeter; Doris Henne-Bruns; Marko Kornmann
Journal:  Int J Colorectal Dis       Date:  2006-03-15       Impact factor: 2.571

7.  The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer.

Authors:  J Kleeff; T Ishiwata; A Kumbasar; H Friess; M W Büchler; A D Lander; M Korc
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

8.  FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities.

Authors:  S Allerstorfer; G Sonvilla; H Fischer; S Spiegl-Kreinecker; C Gauglhofer; U Setinek; T Czech; C Marosi; J Buchroithner; J Pichler; R Silye; T Mohr; K Holzmann; B Grasl-Kraupp; B Marian; M Grusch; J Fischer; M Micksche; W Berger
Journal:  Oncogene       Date:  2008-03-24       Impact factor: 9.867

9.  Dimerization effect of sucrose octasulfate on rat FGF1.

Authors:  N Kulahin; V Kiselyov; A Kochoyan; O Kristensen; Jette S Kastrup; V Berezin; E Bock; M Gajhede
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2008-05-16

10.  Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression.

Authors:  G Chen; X Tian; Z Liu; S Zhou; B Schmidt; D Henne-Bruns; M Bachem; M Kornmann
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.